您好,欢迎来到上海士研管理咨询有限公司
产业峰会 活动服务 营销服务 专家服务
  • 产业峰会:
    以专业团队对产业和市场客观详实地调研为前提,拥有战略性、系统性、全球性的基因,汇集了领导者关注的热点话题与领袖代表,为您提供“一站式”的对话、分享、社交平台!
  • 活动服务:
    致力于成为全球最专业的产业峰会活动提供商,为企业和机构的产业性峰会活动提供一站式专业服务,从调研策划到定制邀请、从营销推广到运营组织,还有项目管理,每项服务都由经验丰富的专业团队匹配长期沉淀的产业资源予以卓越执行,我们注重建立长期而深入的伙伴关系。
  • 营销服务:
    致力于成为全球领先的2B营销服务机构,聚焦产业高端活动、内容、渠道的建设与沉淀,为客户提供一站式整合营销解决方案,助力企业线上线下获客与品牌筑造。我们深信专业团队匹配产业资源带来卓越执行,我们注重建立长期而深入的伙伴关系。
  • 专家服务:
    中国领先的行业专家知识信息服务供应商,为需要专业洞见的商业决策者匹配具有一手经验的行业专家,助力他们以更加明确的目标和坚定的信心做出决策。我们有60万余名专家顾问遍布一百二十多个行业,而且每天还在增加。
会议赞助商
19
2019 - 09 - 06
点击次数:
STC Stem Cell Treatment & Research Institute (STRI) discovered the newly Elicited Stem Cell without side effects (STC-nEPS) with its very own technology. Free from every side effects visible in iPS (induced Pluripotent Stem Cell) and embryonic stem cell, STC-nEPS is expected to bring the quality of life for mankind into a whole new paradigm.
20
2019 - 09 - 06
点击次数:
Bionetix, Inc. (“Bionetix”) is a development stage biotech devoted to the development of innovative small molecule based new drugs. With the aim of providing novel solutions to patients with high unmet medical needs, Bionetix was founded in 2017 and has completed 3 rounds of successful fund-raising campaigns. As a result of the fund-raising, Bionetix has raised about 15M USD until present and developing 2 IND-ready stage candidates (NTX-101, topical glaucoma treatment and NTX-301 oral targeted anti-cancer agent) and other early stage programs. The combination of unique operation system and industrial expertise of Bionetix team enables fast development of the 2 preclinical programs and efficient identification and incubation of novel innovative early stage programs. In 2019, 2 IND applications for bothe NTX-101 and 301 will be submitted and 2 phase I clinical trials are expected in early 2020.
21
2019 - 09 - 06
点击次数:
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The company is investing in indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Collaborations and partnerships are important parts of Medivir's business model and the drug development as well as the commercialization is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. More information about Medivir can be found at www.medivir.com
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务